Dabrafenib,Trametinib
Novartis
['basket study', 'trametinib', 'dabrafenib']
 hot off the press right in time for #aacr23 the tissue agnostic basket study of dabrafenib+ trametinib that led to the fda approval in braf v600 mutant cancers is published in ! a huge win for patients with this rare cancer. i knew this baby 
Oncologist | Associate Prof | Executive Director-Research, MD Anderson Cancer Network | Medical Director, Clinical Center for Targeted Therapy. Tweets = my own.